logo-loader
viewSorrento Therapeutics

Sorrento’s JV with NantWorks is huge validation for G-MAB platform, H.C. Wainwright says

drug_research_350_54908ec728b73.jpg

Sorrento Therapeutics (NASDAQ:SRNE) had its “buy” rating and price target reiterated at H.C. Wainwright after the clinical stage biopharmaceutical company announced a global strategic collaboration with NantWorks to establish a joint venture to develop immunotherapies for cancer and autoimmune diseases.

“We believe the JV announced yesterday is a major validation of both the commercial value of G-MAB antibody platform and management's ability to seek meaningful partnerships,” analyst Swayampakula Ramakanth wrote in a research note to investors today.

The two partners plan to establish an independent company with initial joint funding of $20 million.

NantWorks is the brain-child of Dr. Patrick Soon-Shiong, a biotechnology entrepreneur who was the founder of Abraxis Bioscience that developed Abraxane (2nd generation paclitaxel). Abraxane is currently approved for multiple indications: breast cancer; non- small cell lung cancer; and pancreatic cancer. Dr. Soon-Shiong divested Abraxis BioScience to Celgene for nearly $3 billion in June 2010.

NantWorks is an umbrella organization with an aim to develop personalized medicine for cancer in an attempt to convert the terminal disease into a sustainable chronic condition.

“To that end, Dr. Soon-Shiong is believed to have funded nearly 60 companies and numerous University research programs with nearly $800 million,” Ramakanth said.

According to the Securities and Exchange Commission filing, under the collaboration agreement, Dr. Soon-Shiong's entity is expected to purchase company shares for an aggregate purchase price of nearly $42 million, which translates to a 19.9 percent stake in Sorrento.

Additionally, Sorrento also granted a 3-year warrant to purchase 1.7 million shares at an exercise price of $5.80 that amounts to $10 million.

San Diego, California-based Sorrento ended the third quarter with $44 million in cash and long-term debt of approximately $8 million.

HCW said it has previously expected management to raise about $30 million in 3Q15 to fund future operations as the company progresses towards profitability, which is expected in 2018.

“As a result of this agreement, Sorrento may not need to raise funds,” Ramakanth said.

Quick facts: Sorrento Therapeutics

Price: 1.45 USD

NASDAQ:SRNE
Market: NASDAQ
Market Cap: $205.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Viva Gold kicking off PEA of Tonopah gold project in Nevada

Viva Gold Corp (CVE:VAU) (OTCBB: VAUCF) CEO James Hesketh tells Proactive the Nevada-based gold exploration and development company will begin its Preliminary Economic Assessment of its Tonopah gold project. Hesketh says that based on positive preliminary metallurgical results from its fall...

13 hours, 9 minutes ago

2 min read